PSI Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-150
Closed -$7K 865
2022
Q1
$7K Hold
150
﹤0.01% 523
2021
Q4
$7K Hold
150
﹤0.01% 555
2021
Q3
$7K Buy
+150
New +$7.45K ﹤0.01% 541

Other funds holding XPH

PSI Advisors's XPH Position: Q2 2022 in Review

PSI Advisors sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2022, closing a stake of 150 shares — an estimated $7K sold.

PSI Advisors first reported a position in XPH in Q3 2021 and held it in 3 quarters. The position peaked at $7K in Q1 2022. 71 funds tracked by Wall St. Rank hold XPH as of Q2 2022.

  • PSI Advisors reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2022 after selling out during the quarter.
  • PSI Advisors sold 150 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2022, an estimated $7K.
  • PSI Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q3 2021 and held it in 3 quarters.
  • PSI Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $7K in Q1 2022.
  • 71 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2022.

Based on PSI Advisors's 13F filing for Q2 2022, filed 18 Jul 2022.